Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Overall response rate (ORR), measured after 8 weeks of treatment and prior to surgery. · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | RR 1.75 [0.62, 4.95] | 1 study · 36 participants | Very low |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Time to recurrence — not reported · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Quality of life — not reported · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant treatment vs no neoadjuvant treatment Time to recurrence (TTR),measured by the number of disease recurrence events over time. · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | HR 0.51 [0.22, 1.17] | 2 studies · 171 participants | Very low |
Neoadjuvant treatment vs no neoadjuvant treatment Quality of life ‐ not measured · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment Overall survival (OS), measured by number of deaths over time,Median · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | HR 0.28 [0.03, 2.25] | 1 study · 21 participants | Very low |
Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment Adverse events, · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | 1 study · 14 participants | Low |
Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment Overall response rate (ORR), · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | 1 study · 13 participants | Low |
Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment Time to recurrence (TTR), measured by the number of disease recurrence events over time, · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | HR 0.02 [0, 0.22] | 1 study · 21 participants | Very low |
Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 4.68 [0.57, 38.27] | 2 studies · 79 participants | Very low |
Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo Incidence of serious adverse events · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | 4 studies · 543 participants | Very low |
Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo Short‐term hair regrowth ≥ 75% · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 3.59 [0.19, 66.22] | 1 study · 60 participants | Low |
Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo Incidence of serious adverse events · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 1.54 [0.07, 36.11] | 1 study · 60 participants | Low |
Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 7.54 [3.9, 14.58] | 2 studies · 1200 participants | High |
Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo Incidence of serious adverse events · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 1.47 [0.6, 3.6] | 3 studies · 1224 participants | Low |
Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo Incidence of serious adverse events · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | 2 studies · 79 participants | Very low |
Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 8.49 [4.7, 15.34] | 2 studies · 1200 participants | High |
Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib) Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 1.08 [0.77, 1.52] | 1 study · 80 participants | Very low |
Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib) Incidence of serious adverse events · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | 1 study · 80 participants | Very low |
Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 5 [0.25, 100.89] | 1 study · 78 participants | Low |
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo Incidence of serious adverse events · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 0.33 [0.01, 7.94] | 1 study · 78 participants | Very low |
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 1.16 [0.79, 1.71] | 1 study · 99 participants | Very low |
Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo Health‐related quality of life (AQoL‐8D) · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | 1 study · 36 participants | Very low |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo Incidence of serious adverse events ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil) Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 1.16 [0.79, 1.71] | 1 study · 99 participants | Very low |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil) Incidence of serious adverse events ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone) Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 0.67 [0.13, 3.44] | 1 study · 30 participants | Very low |
Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone) Incidence of serious adverse events · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical hair growth stimulants (minoxidil) vs placebo Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 2.31 [1.34, 3.96] | 2 studies · 202 participants | Very low |
Summary of findings table ‐ Topical hair growth stimulants (minoxidil) vs placebo Incidence of serious adverse events · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | 4 studies · 304 participants | Very low |
Summary of findings table ‐ Topical hair growth stimulants (minoxidil) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical hair growth stimulants (minoxidil) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser) Short‐term hair regrowth ≥ 75% · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 0.31 [0.11, 0.86] | 1 study · 80 participants | Very low |
Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser) Incidence of serious adverse events · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | 1 study · 80 participants | Very low |